奥沙利铂、奈达铂或顺铂同步放化疗在中晚期宫颈癌放疗中的临床应用

发布时间：2018-05-13 23:00

本文选题：奥沙利铂 + 奈达铂　；参考：《临床医药文献电子杂志》2016年39期

【摘要】：目的比较奥沙利铂、奈达铂或顺铂同步放化疗治疗中晚期宫颈癌的疗效和不良反应。方法 2014年9月至2015年9月我院经病理证实的IIB-ⅣA期宫颈癌患者96例,采取随机双盲法进行分组,随机分为奈达铂组32例,奥沙利铂组32例和顺铂组32例。放疗方法采用三维适型调强放疗联合后装治疗,三组于放疗第一周的第三天给药,三组给药同为组每周40mg/m2,比较三组的疗效,毒副反应。结果奥沙利铂组有效率(96.9%)、奈达铂组(93.8%)、顺铂组(96.9%)比较,差异无统计学意义(p0.05)。化疗毒性反应:骨髓抑制(白细胞及中性粒细胞)奥沙利铂组发生率(6.2%)、奈达铂组(7.8%)比较顺铂组(9.8%)稍降低;肾脏毒性反应及胃肠道反应:奥沙利铂组发生率(12.7%)、奈达铂组(18.4%)较顺铂组(39.8%)较低;外周神经毒性:奥沙利铂组(34.8%)明显高于奈达铂组(4.6%)和顺铂组(5.3%)。结论三组增敏化疗方案对局部晚期宫颈癌均有明显效果,但奥沙利铂组及奈达铂组在不良反应及病人耐受性上均较好于顺铂组。
[Abstract]:Objective to compare the efficacy and adverse reactions of oxaliplatin, nedaplatin or cisplatin in the treatment of advanced cervical cancer. Methods 96 patients with IIB- IV A cervical cancer confirmed by pathology from September 2014 to September 2015 were randomly divided into 32 cases of nedaplatin group, 32 cases of oxaliplatin group and 32 cases of cisplatin group. The radiotherapy method was treated with three dimensional adaptive intensity modulated radiotherapy combined with post loading treatment. The three groups were given third days for the first week of radiotherapy, and the three groups were given the same group as 40mg/m2 per week. The efficacy and side effects of the three groups were compared. The results showed that the oxaliplatin group was effective (96.9%), nedaplatin group (93.8%), and cis platinum group (96.9%), the difference was not statistically significant (P0.05). Reaction: myelosuppression (leukocyte and neutrophils) oxaliplatin group (6.2%), nedaplatin group (7.8%) was slightly lower than cisplatin group (9.8%), renal toxicity and gastrointestinal reaction: oxaliplatin group (12.7%), nedaplatin group (18.4%) was lower than cisplatin group (39.8%), peripheral neurotoxicity: oxaliplatin group (34.8%) was significantly higher than Nai. Dplatin group (4.6%) and cisplatin group (5.3%). Conclusion the three groups of sensitized chemotherapy regimens have obvious effect on local advanced cervical cancer, but the adverse reaction and patient tolerance of the oxaliplatin group and nedaplatin group are better than the cisplatin group.

【作者单位】：广西医科大学附属肿瘤医院;
【分类号】：R737.33

【相似文献】